China Biologic Products Begins Operation of its Newly Constructed Plasma Collection Station in Qi He County, Shandon...( TAIAN CITY Shandong China July 9 ...)

TAIAN CITY, Shandong, China, July 9 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("CBP," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that the Company has commenced operations at its newly-constructed plasma collection station in Qi He County, Shandong Province (the "Qi He Station").

The Qi He Station has a daily capacity to collect human plasma from 1000 donors, which is equivalent to approximately 100 metric tons of plasma supply annually. The new facility replaces CBP's existing plasma collection station in Qi He County, which had a capacity to collect an impressive 60 to 80 metric tons of plasma per year. As a result of the historic performance at this station, the Company decided to expand and renovate the station to create a more hygienic environment with greater collection capacity and to ensure a high quality and quantity of human plasma supply. The Company invested $2 million in the new construction.

"We are pleased with the commencement of operations at the new Qi He Station," said Mr. Chao Ming Zhao, the Company's CEO. "We are using the most advanced collection techniques in accordance with international standards. We expect that as the station becomes fully operational, its capacity will increase to the collection of approximately 100 metric tons of plasma supply per year."

About China Biologic Products, Inc.

Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of d
'/>"/>